✨ Free AI Report
Gossamer Bio, Inc.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research Gossamer Bio, Inc.
Company Research

Gossamer Bio, Inc.: Business Overview, Financials & Competitive Analysis

Gossamer Bio is a late-stage clinical biopharmaceutical company focused on developing seralutinib for rare pulmonary diseases, specifically pulmonary arterial hypertension (PAH) and pulmonary hypertension associated w...

Analyst-debate audio for Gossamer Bio, Inc.

AskCyborg analysts argue the bull and bear cases for Gossamer Bio, Inc. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
5/ 10Mixed

Cyborg Score thesis

High-risk clinical-stage biotech with potential upside if FDA approves seralutinib despite missed primary endpoint, but...

Read the full analyst-debate transcript →
Industry Biopharmaceuticals - Rare/Orphan Pulmonary Diseases
3 named competitors
4 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: September 28, 2026
AI-Verified Research
30+ Page Report

Get the Latest Gossamer Bio, Inc. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Gossamer Bio, Inc. Overview

Pro stress-test →

Gossamer Bio is a late-stage clinical biopharmaceutical company focused on developing seralutinib for rare pulmonary diseases, specifically pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company recently announced Phase 3 PROSERA trial results that narrowly missed the primary efficacy endpoint but showed benefit in key subgroups.

Strategic Profile

Pro stress-test →

The company is pursuing a focused development strategy with seralutinib as its lead candidate, jointly developed with the Chiesi Group. Gossamer maintains solid cash position (~$180M) but faces regulatory uncertainty following the PROSERA trial outcome, with plans to engage FDA on path forward. The company also has a pipeline including GB004 (IBD), GB001 (eosinophilic asthma), and GB1275 (oncology).

Competitive Landscape

Pro stress-test →

Gossamer Bio competes in rare/orphan pulmonary disease space against established PAH players (Actelion/Janssen, United Therapeutics, Gilead) and emerging biotech competitors. The company's focused pipeline approach (seralutinib as lead) contrasts with competitors' broader PAH portfolios. Limited direct competition in PH-ILD segment creates differentiation opportunity, though PROSERA trial setback weakens near-term competitive positioning versus established therapies.

Industry Context

Gossamer Bio, Inc. operates in Biopharmaceuticals - Rare/Orphan Pulmonary Diseases.

Key facts

Headquarters: San Diego, US · Revenue: $44.1M · Market cap: $561M

What the analysts stress-tested

The top findings that survived the multi-agent debate for Gossamer Bio, Inc..

  • February 2026 PROSERA Phase 3 results missed primary endpoint (p=0.0320 vs. α=0.025 threshold) but showed +20m benefit in intermediate/high-risk subgroup (p=0.0207)
  • Strong regional variability with North America showing +25.9m improvement; enrollment paused in SERANATA study pending FDA discussions
+2 more stress-tested counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • February 2026PROSERA Phase 3 topline results announced with 13.3m placebo-adjusted 6MWD improvement, missing primary alpha threshold
  • February 2026Company pausing SERANATA enrollment to evaluate regional placebo response discrepancies and plan FDA engagement
  • +2 moreTrack every material event for Gossamer Bio, Inc. as it happens. Explore monitoring →
Get alerted when Gossamer Bio, Inc. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

Ambrisentan, Selexipag, RiociguatEstablished PAH therapies with proven efficacy and market share→Treprostinil, Selexipag combinationDominant PAH player with diversified prostanoid portfolio→ACADIA Pharmaceuticals et al.Rare disease-focused biotech competitors in immunology/inflammation space→

Compare Gossamer Bio, Inc. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Gossamer Bio, Inc. operates in Biopharmaceuticals - Rare/Orphan Pulmonary Diseases. See how the rest of the sector scores on the Cyborg framework.

Browse Biopharmaceuticals - Rare/Orphan Pulmonary Diseases research →
NEW · MCP server

Ask your AI assistant about Gossamer Bio, Inc.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Gossamer Bio, Inc. and its top competitor on Cyborg Score”
“What did Gossamer Bio, Inc. do this quarter?”
“Is Gossamer Bio, Inc. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg builds confidence

⚔

Analyst debate, not single-author opinion

Every report is stress-tested by a panel of AI analysts arguing across 11 dimensions. The output is the part of the case that survived pushback.

📊

Recalibrated weekly

The Cyborg Score is recomputed weekly against fresh data. Recent material developments are continuously tracked and surfaced.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The same company gets the same score from any analyst running the framework.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, news flow, and proprietary analyst signals. Read the methodology →

Frequently asked questions

What does Gossamer Bio, Inc. do?+
Gossamer Bio is a late-stage clinical biopharmaceutical company focused on developing seralutinib for rare pulmonary diseases, specifically pulmonary arterial hypertension (PAH) and pulmonary hypertension associated w...
What is Gossamer Bio, Inc.'s Cyborg Score?+
Gossamer Bio, Inc. has a Cyborg Score of 5/10 (Mixed). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Gossamer Bio, Inc.'s main competitors?+
Named competitors include Ambrisentan, Selexipag, Riociguat, Treprostinil, Selexipag combination, ACADIA Pharmaceuticals et al.. The full competitive landscape is in the AskCyborg report.
How can I get the full Gossamer Bio, Inc. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Gossamer Bio, Inc. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Gossamer Bio, Inc. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

More Biopharmaceuticals - Rare research

Companies in the same sector and named competitors, ranked by Cyborg Score.

5Gossamer Bio, Inc.